New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab’s Nebokitug in Systemic Sclerosis

Nebokitug's Potential in Treating Systemic Sclerosis: Chemomab Therapeutics announced new evidence supporting nebokitug (CM-101) as a promising treatment for systemic sclerosis (SSc), an autoimmune disease with no approved therapies. The findings, to be presented at the CORA 2025 conference, highlight the role of CCL24 in SSc pathology and suggest that inhibiting it may reduce inflammation and fibrosis.

Clinical Trial Progress and Future Directions: Nebokitug has shown positive results in multiple clinical trials, including a Phase 2 trial for primary sclerosing cholangitis (PSC), reinforcing its potential as a dual anti-inflammatory and anti-fibrotic therapy. The company is preparing for further trials and has received regulatory designations for both PSC and SSc treatments.